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Coronary artery disease is the leading overall cause of mortality for women and increases
dramatically after menopause. Estrogen has many beneficial cardiovascular actions although
concerns have been raised about its effects on the progression of breast and uterine neoplasms
and its tendency to increase coagulability. Selective estrogen agonists may be superior to
conventional estrogens. A dietary source of a partial estrogen agonist is the plant-based group
of phytoestrogens, which include isoflavones, lignans and coumestans. Phytoestrogens have a
similar structure to estradiol and have weak affinity for the estrogen receptor. Epidemiologic
data indicate that women ingesting high amounts of phytoestrogens, particularly as isofla-
vones in soy products, have less cardiovascular disease, breast and uterine cancer and
menopausal symptoms than those eating Western diets. Preclinical and clinical studies have
found that isoflavones have lipid-lowering effects as well as the ability to inhibit low-density
lipoprotein oxidation. They have been shown to normalize vascular reactivity in estrogen-
deprived primates. Furthermore, phytoestrogens have antineoplastic effects with inhibition of
cellular proliferation as well as angiogenesis, properties that could be protective against cancer
development. Finally, menopausal symptoms and bone density may be favorably influenced by
phytoestrogens. In summary, phytoestrogens, in the form of dietary isoflavones, represent a
new area to explore in pursuit of nutritional approaches to cardiovascular protection. (J Am
Coll Cardiol 2000;35:1403–10) © 2000 by the American College of Cardiology
ESTROGEN AND
CARDIOVASCULAR DISEASE IN WOMEN
Coronary artery disease (CAD) is the leading cause of death
among women in developed nations. It is well recognized
that its incidence increases substantially after menopause,
purportedly due to the loss of estrogen’s protection. The
increased incidence of cardiovascular events in younger,
surgically postmenopausal women supported this hypothe-
sis. The role of estrogen deficiency in cardiovascular disease
(CVD) was further indicated by preclinical studies demon-
strating that estrogen could inhibit atherosclerosis.
Population-based, observational studies revealed that the
risk of cardiovascular events in women taking hormones was
cut in half (i.e., a relative risk of 0.5), providing support for
a benefit of estrogen (1–3). Subsequently, a number of
clinical trials have demonstrated that, in postmenopausal
women, estrogen has favorable effects upon lipid profiles,
endothelial cell function, vascular reactivity and hemostatic
factors. The Postmenopausal Estrogen/Progestin Interven-
tions Trial (4) convincingly showed that women taking
estrogen replacement therapy experienced a significant de-
cline in levels of low-density lipoprotein (LDL) and li-
poprotein(a) while the high-density lipoprotein (HDL)
favorably increased. Estrogen influences vascular reactivity
through effects on smooth muscle cells as well as the
endothelium. The multiple effects of estrogen on vasomotor
responses were recently summarized by Farhat et al. (5) and
include relaxation of precontracted vessels, inhibition of
calcium entry, enhanced expression of nitric oxide synthase,
stimulation of prostacyclin production and prevention of
myointimal hyperplasia. Estrogen has also been shown to
potentiate endothelium-dependent vasodilation of the cor-
onary (6,7) and brachial (8,9) arteries in both postmeno-
pausal women and primates (10–12). Because of the extent
of this supportive data, in the last decade, postmenopausal
hormone replacement therapy (HRT) has been used in an
effort to reduce CVD in women.
Today, the evidence of estrogen’s efficacy for prevention
of CVD has been called into question due to the negative
results of the Heart and Estrogen/Progestin Interventions
Trial (13). In this first randomized clinical trial performed
in women with known CAD, cardiovascular events were not
prevented by combination therapy of oral estrogen and
progesterone, and, surprisingly, early events were actually
increased in treated patients. This study, as well as others,
underscored the known risks of estrogen therapy, which
include hypertriglyceridemia, endometrial hyperplasia, tu-
morigenesis and hypercoagulable states.
Unopposed estrogen therapy causes symptomatic and
premalignant endometrial hyperplasia, which can be ame-
liorated with the addition of progesterone although at a cost
of attenuating the lipid-lowering effect of estrogen (4). The
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modest, but nevertheless concerning, increased incidence of
breast cancer in women taking estrogens is a major limita-
tion of this prophylactic therapy (14). Angiogenesis, a
fundamental process necessary for tumorigenesis as well as
atherosclerotic progression, can be enhanced by estrogen
(15), which induces expression of cellular adhesion mole-
cules and organization of endothelial cells into primitive
blood vessels, upon which tumors depend. The effect of
estrogen upon the coagulation system is variable. Platelets
incubated with estradiol manifest decreased adherence (16)
and aggregation (17) although studies in women on HRT
have not shown similar antiplatelet effects (18,19). Other
reports have noted decreased fibrinogen (4) and decreased
plasminogen activator inhibitor (20–22) levels in women
taking HRT, which may be protective, although thrombotic
events are actually increased in this population (13).
PHYTOESTROGENS: AN ALTERNATIVE TO ESTROGEN?
Given the demonstrated risks to conventional HRT, many
women and their practitioners have been in search of
alternatives. Phytoestrogens are naturally occurring estro-
gens that may have beneficial effects on the cardiovascular
system and may also alleviate common illnesses afflicting
women, such as menopausal symptoms, osteoporosis and
breast cancer (Table 1). Phytoestrogens may have advan-
tages over conventional estrogens in that they may lower
LDL cholesterol without inducing hypertriglyceridemia
(23); they may relieve menopausal symptoms without in-
creasing the risk of uterine or breast neoplasia (24); they
may enhance vascular function without accelerating patho-
logical angiogenesis (25); and there are no reports of
increased thrombotic events. There is not yet enough
evidence from large randomized clinical trials to make an
unqualified recommendation about the use of phytoestro-
gens, but accumulating data indicate that phytoestrogens
may be an alternative therapy for postmenopausal women at
risk for CVD. The evidence for cardiovascular benefit of
phytoestrogens is the subject of this review.
PHARMACOLOGY AND
PHYSIOLOGY OF PHYTOESTROGENS
Phytoestrogens are naturally occurring, plant based diphe-
nolic compounds that are similar in structure and function
to estradiol (Fig. 1). There are many types of phytoestro-
gens, but the major categories include isoflavones, lignans
and coumestans. Common and significant sources of phy-
toestrogens are soybeans (isoflavones), cereals and oilseeds
such as flaxseed (lignans) and alfalfa sprouts (coumestans).
These estrogen-like compounds were identified in the
1940s, when an epidemic of infertility among sheep was
investigated. The animals were grazing on clover (Trifolium
sp)—a plant with a high content of formononetin, which is
converted by ruminal bacteria to isoflavones, the predomi-
nant type of phytoestrogens.
Abbreviations and Acronyms
CAD 5 coronary artery disease
CVD 5 cardiovascular disease
HDL 5 high density lipoprotein
HRT 5 hormone replacement therapy
ICAM-1 5 intercellular adhesion molecule-1
LDL 5 low-density lipoprotein
VCAM-1 5 vascular cell adhesion molecule-1
VLDL 5 very low density lipoprotein
Table 1. Effects of Phytoestrogens in Basic, Animal and Human
Studies*
Preclinical Studies
2 Cholesterol (44,45,50)
2 LDL oxidation (46)
1 Antioxidant enzymes (48)
2 Atherosclerotic lesions (45)
1 Vascular reactivity (54,55)
2 Platelet aggregation (51,52)
2 Expression of ICAM-1 and VCAM-1 (49)
2 Angiogenesis (25,61)
2 Neoplastic proliferation (62–66,68)
2 Bone loss (88,89)
Clinical Studies
Beneficial
2 Cholesterol (23,41,42)
2 LDL oxidation (47)
2 Perimenopausal hot flashes (56)
2 Cancer incidence (69,73–84)
1 Bone mineral density (90)
?Detrimental
1 breast secretions (85)
1 proliferation of breast epithelium (86)
*See text for details. ICAM-1 5 intercellular adhesion molecule; VCAM-1 5
vascular cell adhesion molecule.
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The most common and best studied phytoestrogen is the
class of isoflavones. The most abundant active components
of isoflavones are genistein and daidzein. These agents
appear to have selective estrogenic actions, i.e., in some
tissues they display proestrogenic responses, whereas in
others, they inhibit estrogenic effects. The recent identifi-
cation of a second subtype of estrogen receptor lends
support to the theory of selective estrogenic action (26,27).
Estrogenic activity is dependent on the affinity of binding to
the estrogen receptors, which is determined by the presence
of the aromatic ring as well as hydroxyl groups at specific
sites (28). Compared with estradiol, genistein and daidzein
bind estrogen receptors with 100 and 1,000 times less
affinity, respectively (29). Nevertheless, in the quantities
that can be consumed in the diet, isoflavones can have
biological effects. Antiestrogenic effects may be due to
competitive inhibition at the estrogen receptor, interference
with gonadotrophins, inhibition of estrogen synthesis or
increased synthesis of estrogen-binding protein. Phytoestro-
gens do not have feminizing effects in male primates as
reflected by unchanged weights of the reproductive organs
in these animals, although prenatal exposure of rats resulted
in diminished weights of ovaries and uteri in females (30).
Isoflavones are widely consumed by Asian populations,
predominantly in the form of soy. The typical concentration
of genistein in soy foods is 1 to 2 mg per g of protein, and
Asians consume 20 to 80 mg of genistein per day in the
usual diet. By contrast, the average American ingests only 1
to 3 mg per day (31). Dietary studies can be inconsistent,
however, as there is significant variation of isoflavone
content between varieties of soy beans, the particular crop,
as well as the processessing methods. Isoflavones are inactive
molecules when in the form of glycosides (genistin, daid-
zin), but as aglycones (genistein, daidzein) intestinal absorp-
tion is possible. Intestinal absorption varies greatly between
individuals, which may be related to the content of dietary
fiber and the state of intestinal microflora. After absorption,
isoflavones are reconjugated to glucuronides and excreted
unchanged in the urine (32). Plasma levels increase 6 1/2 h
after ingestion in a dose dependent fashion (33), and urinary
levels increase dramatically after supplemented diets have
begun. For example, urinary levels of genistein increased
from 0.8 umol/day to 26 umol/day and daidzein from 0.3
umol/day to 23 umol/day after a nine day ingestion of 100 g
tofu and 45 g soy protein isolate (34).
Concentrations of the phytoestrogens and their metabo-
lites can be measured in urine, plasma and other bodily
fluids and vary widely, even during controlled nutrition
studies. As dietary phytoestrogen metabolism is profoundly
influenced by gastrointestinal flora, antibiotic use or bowel
disease will modify metabolism and therefore, bioavailabil-
ity. Equol is a metabolite of daidzein, which shows enor-
mous variation in urinary excretion. Some studies have
distinguished individuals as either equol excreters or non-
excreters because the excretion rates vary so substantially
(35). However, this appears to be independent of the
dose-dependent excretion of genistein and daidzein.
Chronic ingestion of isoflavones also affects their metabo-
lism. For example, after one month of a high soy diet (36 oz
of soymilk containing 100 mg daidzein and 115 mg
genistein), young, healthy women exhibit increased absorp-
tion rates, as indicated by a higher peak serum level, but also
accelerated excretion based on the percentage of ingested
isoflavone recovered in the urine (36).
There are many other natural agents classified as phy-
toestrogens, based on their structure or function. Resvera-
trol is another potentially important phytoestrogen with a
structure similar to diethylstilbesterol. Resveratrol is present
in grapes and, therefore, wine and has been proposed to be
the agent responsible for the “French-paradox” (37). The
French paradox derives from the epidemiological observa-
tion that the French and Italian populations suffer from less
CVD than other Europeans and Americans, despite a
relatively high intake of dietary fat. Resveratrol has been
shown to bind to human estrogen receptors, initiate tran-
scriptional activity dependent on the estrogen-response
element, activate estrogen-regulated genes, cause prolifera-
tion of estrogen-dependent breast cancer cell lines and
inhibit the expression of vascular cell adhesion molecule-1
(VCAM-1) and intercellular adhesion molecule-1
(ICAM-1) in human endothelial cells (38). Its action can
also be inhibited by estrogen antagonists such as tamoxifen
(39).
BENEFICIAL CARDIOVASCULAR EFFECTS
Favorable effects of phytoestrogens on lipid profiles, vascular
reactivity, thrombosis and cellular proliferation have been
reported. It is plausible that the lower incidence of CAD in
populations ingesting diets high in phytoestrogen is due to
an improved lipid profile. In a study of 24 healthy normo-
cholesterolemic men assigned to either a low fat soy diet or
low fat animal protein diet, no difference was observed in
total cholesterol levels (40), but when patients with type II
hyperlipoproteinemia (mean TC 409 mg/dL) were placed
on high soy diets for four weeks, the total cholesterol and
LDL decreased by 16%. These changes were attributed to
increased LDL degradation (41). A later study designed
specifically to examine diets differing only in their protein
source randomly assigned healthy men to diets either: 1)
high in fat, 2) low in fat with soy protein, or 3) low in fat
with animal protein. Both of the low fat diets decreased
total cholesterol levels and blood pressure compared with
the high fat diet, but the soy protein had a more potent
hypocholesterolemic effect (10% vs. 5% decline in total
cholesterol) (42).
Although some published studies have failed to observe a
fall in cholesterol values on a soy-based diet, a meta-analysis
of 38 trials of soy protein consumption in humans revealed
an improvement in total cholesterol by 9% and LDL by
13%, as well as a decrease in triglyceride levels of 10% (23).
In these trials, the average intake of soy was 47 g/day. The
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extent of reduction was dependent upon the baseline level of
cholesterol; for example, in subjects with moderate hyper-
cholesterolemia (259–333 mg/dL), a decrease in total cho-
lesterol of 7.4% was observed, whereas subjects with severe
hypercholesterolemia (.335 mg/dL) achieved a decline of
19.6%.
Three theories of possible mechanisms for the hypocho-
lesterolemic effects of phytoestrogens have been proposed.
One explanation is that phytoestrogens cause an increase in
the excretion of bile acids and, therefore, enhance removal
of LDL. Others have proposed that phytoestrogens initiate
a hyperthyroid state, supported by the finding in some
studies of increased free thyroxine levels after feeding soy
proteins to animals (43). The third and best supported
mechanism of phytoestrogen lipid-lowering is that of al-
tered hepatic metabolism with augmented LDL and VLDL
removal by hepatocytes. Sirtori et al. (44) demonstrated
substantial reductions in cholesterol levels with enhanced
LDL degradation and increased binding of radiolabeled
LDL to receptors. A study using the LDL-receptor defi-
cient mouse has provided further support for an effect of
isoflavones on LDL receptor activity (45). When normo-
cholesterolemic C57BL/6J mice were fed a high cholesterol,
isoflavone-poor diet, they developed hyperlipidemia and
intimal lesions in the proximal aorta. However, those
animals fed an isoflavone-rich diet exhibited a decrease in
total cholesterol and VLDL cholesterol. By contrast, this
benefit of an isoflavone-rich diet was not observed in LDL-r
null mice, suggesting that isoflavones may reduce lipid levels
by increasing the activity of the LDL receptor. Further-
more, there was a 50% reduction in intimal lesion area in
isoflavone treated C57BL/6J but not LDLr-null mice, again
implicating an effect of isoflavones on LDL receptor activity
in conferring cardiovascular protection.
Isoflavones may also inhibit oxidation of LDL. Kapiotis
and colleagues (46) observed that LDL oxidation products,
assayed as Thiobarbituric Acid–Reactive Substances in ei-
ther cell free or endothelial cell systems, were strongly
inhibited by genistein, somewhat inhibited by daidzein but
not affected by genistin (the glycosylated form of genistein)
or control. Furthermore, both genistein and daidzein were
found to protect against cytotoxic effects of oxidized LDL as
assessed by cellular morphologic features and lactate dehy-
drogenase release by cultured endothelial cells. A trial in
humans enrolling healthy volunteers consuming three soy
bars per day for two weeks (total 36 mg genistein and 21 mg
daidzein per day) demonstrated a significant amount of
genistein and daidzein within the LDL fractions, as well as
a significant prolongation of the lag time to LDL oxidation,
implying an antioxidant effect (47). Genistein has also been
shown to inhibit hydrogen peroxide production and increase
the activity of antioxidant enzymes, such as catalase, super-
oxide dismutase, glutathione peroxidase and glutathione
reductase. Furthermore, genistein, and to a lesser degree
daidzein, can inhibit superoxide anion generation by xan-
thine/xanthine oxidase (48).
Atherosclerosis is initiated by monocytes binding to the
endothelium and migrating into the intimal layer to develop
into foam cells. The adhesiveness of endothelial cells is due
to lipid-induced, oxidant-sensitive transcription of adhesion
molecules and chemokines, which promote monocyte bind-
ing. This binding is reliant upon intercellular signalling and
oxidant-sensitive transcription of adhesion molecules. Phy-
toestrogens may further protect against atherosclerosis by
interfering with these initial processes. Although scant
information has been published thus far, genistein is capable
of inhibiting the expression of ICAM-1 and VCAM-1 on
human endothelial cells co-cultured with monocytes (49).
Furthermore, by reducing oxidative stress, it is possible that
phytoestrogens deactivate the transcriptional pathways lead-
ing to the expression of genes involved in monocyte adhe-
sion and infiltration.
The response to isoflavones is influenced by gender.
Monkeys that were fed an atherogenic diet followed by a soy
protein phytoestrogen-rich diet in a six-month crossover
trial had a lowering of LDL and VLDL levels compared
with control values. However, female animals additionally
manifested an increase in HDL, decrease of lipoprotein (a),
lower LDL molecular weight, decrease in apolipoprotein B,
AI, A2 and no hypertriglyceridemia (50).
Phytoestrogens may have less prothrombotic tendencies
than the currently used formulations of estrogen. In vitro
studies of genistein and daidzein reveal decreased platelet
aggregation by collagen and thromboxane (51,52), which
may be due to an inhibition of binding of the thromboxane
receptor or diminished tyrosine phosphorylation. However,
in a small study of 20 healthy, normocholesterolemic men
fed a soy diet for 28 days, a significant increase in plasma
levels of genistein and daidzein occurred but without a
change in platelet aggregation (53). It was suggested that on
such supplements, serum levels of the active compound do
not reach levels comparable with those required to affect
platelet aggregation in the in vitro studies.
Preclinical studies suggest that vascular reactivity may be
favorably influenced by phytoestrogens. Primates manifest
an improvement in endothelium mediated vasodilation
when treated with phytoestrogens. Specifically, postmeno-
pausal monkeys on a phytoestrogen-rich diet for six months
exhibited normal coronary artery vasodilation in response to
locally-administered acetylcholine, whereas a vasoconstric-
tive response was seen in male animals as well as female
monkeys with a low intake of phytoestrogens (54). In vitro
studies of isolated vessels have examined the mechanisms of
phytoestrogen-induced vasodilation (55). Estradiol-17B,
genistein and daidzein were all found to relax mesenteric
arterial rings of rats in a dose dependent manner. Consistent
with receptor affinity assays, estradiol was the most potent
vasodilator, followed by genistein, then daidzein. In these
isolated arterial rings, response was independent of gender.
The vasorelaxation was endothelium-independent and was
not blocked by antagonists of nitric oxide or prostacyclin
production.
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Estrogen withdrawal results in symptomatic hot flashes in
perimenopausal women and may represent an alteration in
vasomotor response to endocrinologic stimuli. As a popu-
lation, Asian women experience less perimenopausal hot
flashes, a benefit attributed to phytoestrogens. Also, in a
randomized study of 58 postmenopausal non-Asian women,
those consuming soy protein supplementation in the form
of 45 g of soy flour per day suffered less from hot flashes
than control women (56), invoking another potential use for
phytoestrogen supplementation.
Phytoestrogens may have electrophysiological effects as
well. The sensitivity of ventricular myocytes to beta-
adrenergic stimulation can be enhanced by genistein and
daidzein, implicating a role of tyrosine kinase regulation of
cardiac ion channels (57). However, there is, as yet, no
known clinical effect of phytoestrogens on arrhythmias.
BENEFICIAL NONCARDIOVASCULAR EFFECTS
The most powerful argument against the routine use of
HRT for postmenopausal women is the increased risk of
cancer. Phytoestrogens do not appear to increase the risk of
breast and uterine cancer; in fact, observations from in vitro
and animal studies indicate that phytoestrogens may have
antineoplastic effects. These antineoplastic effects may be
related to suppression of angiogenesis, inhibition of tyrosine
kinase activity, or partial antagonism of estrogen receptors.
Tumor growth is dependent upon angiogenesis, which is a
tightly regulated, complex process (58). Endothelial cells
play a pivotal role in angiogenesis, which requires endothe-
lial cell attachment, migration, proliferation, protease pro-
duction and subsequent organization into vascular struc-
tures. Whereas estradiol has been demonstrated to augment
various steps in the angiogenic process (59), components of
phytoestrogens may actually inhibit angiogenesis. Genistein
reduces basic fibroblast growth factor induced endothelial
cell migration (60) and capillary-like tube formation, per-
haps by inhibiting tyrosine kinase or by decreasing levels of
plasminogen activator and plasminogen-inhibitor and, thus,
interrupting the tightly regulated balance of proteolytic
degradation (25). In the setting of atherosclerosis, the
enhancement of angiogenesis may hold therapeutic poten-
tial to relieve myocardial ischemia by increasing blood flow.
Therapeutic angiogenesis has become a very active field of
research with ongoing clinical studies designed to explore
the safety and efficacy of various growth factors, delivered as
protein or gene therapy. However, the neovascularization of
atherosclerotic plaques could lead to plaque instability and
resultant negative consequences. Indeed, Folkman and col-
leagues (61) have recently demonstrated that endostatin, an
inhibitor of angiogenesis, can slow the development of
aortic lesions in the hypercholesterolemic apoE-deficient
mouse.
Phytoestrogens, particularly genistein, also have antipro-
liferative effects. This has been demonstrated in multiple
cell lines including prostate cancer cells (62), breast cancer
cells (both estrogen receptor positive as well as negative)
(63) and other tumor cells (neuroblastoma, sarcoma, reti-
noblastoma), as well as vascular endothelial cells and fibro-
blasts (64). The in vitro effect of genistein, a known tyrosine
kinase inhibitor, on breast cancer cell growth was evaluated
by quantifying DNA and total cellular protein levels com-
pared with the effect of estrogen (65). Over a range of 0.1 to
1 uM, genistein had a stimulatory, estrogen-like effect on
estrogen receptor positive cell proliferation, but at .10 uM
of genistein, growth was totally inhibited. However, estro-
gen receptor negative cells showed no response to, or
possibly inhibition by, genistein even at low concentrations
(10 nM–1 uM). Another group of investigators demon-
strated that the effect of phytoestrogens in inhibiting pro-
liferation is a reversible, cytostatic effect (60). Even at
concentrations of up to 200 umol/L, genistein was not
cytotoxic in quiescent cells. The mechanism of this inhibi-
tory effect of genistein is speculated to be its antagonism of
tyrosine kinase. However, other investigators have observed
a genistein-induced inhibition of proliferation despite ade-
quate levels of tyrosine kinase activity (66). This antiestro-
genic effect of phytoestrogens may provide protection anal-
ogous to the estrogen partial-agonist, tamoxifen, in the
treatment or prevention of breast cancer. Animal models
support an antineoplastic role for phytoestrogens; for exam-
ple, rats given soy-derived phytoestrogens develop fewer
mammary tumors after exposure to carcinogens (67).
The evidence that phytoestrogens may protect against
cancer development derives largely from in vitro studies of
human cell lines, animal models of neoplasia and epidemi-
ological data. Overall, most epidemiological studies have
indicated a protective effect of soy ingestion (68). Epidemi-
ologic studies reveal a decreased incidence of breast, prostate
and endometrial cell cancer in populations ingesting high
amounts of soy. Asian women develop breast cancer four to
six times less often than their American counterparts, but
this advantage wanes after living in the U.S. (69–71),
implicating a protective influence of traditional diets. Fur-
thermore, breast cancer patients have lower urinary isofla-
vone levels, suggesting that they have decreased ingestion,
absorption, excretion or overall bioavailability of isoflavones
compared with women without breast cancer (72,73). The
benefits of dietary phytoestrogens may extend to other
neoplasms, and to men as well as women. Hawaiians of
Japanese descent who maintain a traditional diet with high
soy content have less risk of prostate cancer than non-
Japanese Hawaiians (74), and consumption of a diet en-
riched with lignans (legumes and fruit) is associated with
decreased prostate cancer risk in Seventh Day Adventists
(75). If these beneficial effects of diet are due to phytoestro-
gen content, the benefit may be linked to the observation
that certain phytoestrogens (i.e., genistein and biochanin A)
have been observed to inhibit the growth of androgen-
dependent and independent human prostate cancer cell lines
(62). High soy consumption (as tofu, miso or soybean
sprouts) is associated with reduced risks of lung, gastric and
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rectal cancer in Chinese and Japanese men and women
(76–83). Rates of breast, ovarian, prostate and colon cancer
are negatively correlated with cereal and phytoestrogen
intake when comparing cancer mortality rates and food
availability data among countries (84).
Despite the plethora of evidence that phytoestrogens have
antineoplastic effects, two concerning clinical reports have
been published. One study reported the effect upon monthly
nipple aspirations in pre- and postmenopausal women
ingesting soy protein containing 38 mg genistein/day (85).
An increased total fluid volume was recovered in premeno-
pausal women and postmenopausal women during and after
phytoestrogen treatment. Additionally, there was an in-
creased frequency of cellular hyperplasia in the aspirate.
However, there were no controls in this study, and the
aspirations themselves could account for the abnormalities.
Nevertheless, the study does raise some concern for high
risk patients. Another report of 29 women taking 60 g of
soybean supplement daily found increased proliferation of
breast lobular epithelium assessed by 3H-thymidine labeling
(86). However, there are no human studies that have linked
dietary phytoestrogens to the development of breast cancer.
Similar to other selective estrogen antagonists, phy-
toestrogens may also protect against osteoporosis. Studies of
aging or ovariectomized rats have shown that a soy protein
diet protects against bone loss (87,88) although this effect is
not mimicked by supplemental genistein (89), suggesting
that some other component of soy protein may be respon-
sible for the beneficial effect. However, a trial in postmeno-
pausal women revealed an increase in bone mineral density
in the lumbar spine after isoflavone supplementation (90).
SUMMARY
To conclude, there are accumulating data from epidemio-
logic studies, human trials, animal models and in vitro
analysis to support the increased use of phytoestrogens,
particularly in individuals at high risk of CVD. Favorable
effects upon lipid profiles, vascular reactivity, angiogenesis
and tumorigenesis have been attributed to the isoflavones
genistein and, to a lesser extent, daidzein. The increasing
use by the general public of alternative therapies including
these agents necessitates a greater understanding of their
effects, as well as a need for clinical investigations to guide
practitioners in their recommendations. The current state of
knowledge indicates that the world of plant based estrogens
has much to offer, but significant questions remain. Do
phytoestrogen-enriched diets alleviate symptoms of athero-
sclerosis or reduce the risk of vascular events? If so, can this
effect be attributed to a specific phytoestrogen, and can the
benefit be mimicked by supplementation with that specific
compound? How do the benefits of phytoestrogen therapy
on the lipoprotein profile or vascular reactivity compare with
other therapies? Which subgroups of the population might
benefit most from phytoestrogen use? What are the side
effects of such supplementation? Is it safe for women with a
personal or family history of breast or uterine cancer to use
phytoestrogens? Answers to these questions, which could be
obtained by large, randomized clinical trials, may lead to a
greater understanding of the hormonal effects upon the
cardiovascular system and provide women with more op-
tions for preventative treatment. In the interim, it seems
reasonable to recommend that women at high risk of
cardiovascular morbidity and mortality, particularly those
without a personal or family history of breast or uterine
cancer, increase their consumption of foods rich in phy-
toestrogens such as soy protein.
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